Moderna eyes PhIII start for combo mRNA jab targeting Covid and flu after PhI/II success
Moderna’s combination vaccine candidate for Covid-19 and influenza, mRNA-1083, has shown early potential in a mid-stage trial, sparking plans for registrational development later this year.
The ongoing Phase I/II trial is comparing mRNA-1083 to a standard dose of Fluarix or high-dose Fluzone, depending on patient age, and Moderna’s own Spikevax booster for Covid-19.
The combination vaccine is one of 15 products the US biotech aims to bring to market over the next five years. Moderna’s ambitious plans also include advancing up to 50 mRNA programs into the clinic within the same timeframe. But its jab candidate for influenza only, mRNA-1010, has yielded mixed data in the past, although it has since succeeded at Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.